A Single-arm, Open-label Study of Avastin Plus Xeloda on Objective Treatment Response in Patients With Advanced or Metastatic Liver Cancer Who Have Had no Previous Cytotoxic Chemotherapy

Trial Profile

A Single-arm, Open-label Study of Avastin Plus Xeloda on Objective Treatment Response in Patients With Advanced or Metastatic Liver Cancer Who Have Had no Previous Cytotoxic Chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 20 Dec 2013 New source identified and integrated (ClinicalTrials.gov; NCT02013830)
    • 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
    • 08 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top